Estrategia en Cáncer del Sistema Nacional de Salud

Objectives

Spain’s National Health System Cancer Strategy seeks to reduce the impact of cancer, improve prevention and care, and address geographical inequalities through quality, equity and cohesion across the health system.[1][2][3]It is grounded in national health legislation requiring comprehensive plans spanning prevention, diagnosis, treatment and rehabilitation.[1]

• Strengthen health promotion and cancer prevention by addressing tobacco, alcohol, unhealthy diet, physical inactivity, overweight and obesity, ultraviolet exposure, occupational carcinogens and radon.[4][5][6][7]
• Expand evidence-based, quality-assured population screening for breast, cervical and colorectal cancer, while assessing additional screening only where benefits outweigh harms.[8][9][10]
• Improve healthcare through rapid diagnosis, timely treatment, multidisciplinary care, coordination between primary and hospital services, personalised treatment and equitable access to innovation.[4][11][12]
• Concentrate rare-tumour, high-complexity and paediatric cancer care in experienced reference units and cooperative networks to improve outcomes and reduce unwarranted variation.[13][14][15]
• Support survivorship, rehabilitation, psychosocial and social care, fertility preservation, palliative care and coordinated long-term follow-up for patients, families and carers.[16][17][18]
• Strengthen cancer data, information systems, population-based registries and research to support prevention, planning, evaluation, clinical outcomes and innovation.[19][20][21]

The Strategy is organised around five strategic lines: health promotion and cancer prevention; healthcare; healthcare for children and adolescents; cancer data and information; and research.[22]Its objectives are intended to be measurable, quantifiable and capable of update, with actions defined as activities needed to achieve them.[23]

Key quantified ambitions include hepatitis B vaccination coverage above 95% among children aged 12 months, complete human papillomavirus vaccination coverage of at least 80% among adolescents aged 15 years, breast-screening participation of at least 70%, cervical-screening participation of at least 70%, and colorectal-screening participation of at least 65%.[24][10]Cervical screening is intended to move fully to organised, invitation-based delivery, with programmes started before 2024 and full invitation coverage before 2029.[10]

Implementation

Implementation relies on nationally agreed standards delivered through Spain’s autonomous communities, coordinated within the National Health System and supported by multidisciplinary professional, patient, research and public-health participation.[1][22]The Strategy combines population prevention, organised screening, integrated care pathways, specialist referral networks, information systems, quality assurance and research collaboration.[8][25][20]

• Coordinate governance through the Institutional Committee, representing the 17 autonomous communities, Ceuta and Melilla, Ministry of Health departments and the Carlos III Health Institute, and through a Technical Committee of scientific societies, experts and patient representatives.[22]
• Use the Follow-up and Evaluation Committee, established in 2007, to link technical and institutional governance and support monitoring and updates.[23]
• Deliver prevention through a Health in All Policies approach, intersectoral action, proportionate equity measures, citizen participation, primary-care counselling and links to community resources.[26][27]
• Organise screening as a complete pathway from identifying and inviting the target population through testing, assessment of positive results and treatment, rather than relying on opportunistic testing.[8]
• Establish multidisciplinary tumour units or committees in every hospital treating cancer, with defined membership, clinical protocols, documented treatment decisions, patient information, referral and follow-up arrangements.[28][29]
• Develop rapid referral channels from primary care to hospital services, with training for primary-care professionals and recommended time standards for first assessment, diagnosis and treatment.[12][30]
• Designate Centres, Services and Units of Reference within the National Health System for highly specialised treatment, supported by accreditation, patient registries, audits, annual follow-up and cross-regional referral arrangements.[31][32]
• Organise childhood and adolescent cancer care through regional coordination committees, designated paediatric onco-haematology units, formal networks, multidisciplinary teams and developmentally appropriate transition to adult services.[33][34][35]

Operationally, the Strategy promotes shared electronic health records, networked collaboration between primary care, local hospitals and reference centres, and case-manager roles to coordinate clinical, psychological, social, family, employment and financial support.[36][37][38]Precision oncology is to provide equitable access to clinically indicated genetic and molecular testing, reliable interpretation, pathology quality assurance and expert second reading for rare tumours, although a complete national financing and organisational model remains to be defined.[39][40]

Monitoring uses process and outcome indicators, autonomous-community reporting, audits, population surveys, screening information systems, hospital data and cancer registries.[23][33][41]Core measures include prevention behaviours; vaccination coverage; screening invitation, participation and detection; diagnostic and treatment intervals; multidisciplinary assessment; reference-unit designation; survival; incidence; mortality; years of potential life lost; and equity.[41][42][43]Population-based registries and the Spanish Network of Cancer Registries support incidence, prevalence and survival monitoring, while the Spanish Registry of Childhood Tumours supports childhood cancer surveillance.[20][44][45]

Specified operational targets include a first hospital visit within seven calendar days of primary-care referral, pathological diagnosis or exclusion within 15 days of the first hospital visit, and molecular diagnosis within four weeks where required.[12][46]Recommended median intervals from completed diagnosis to treatment are two weeks for surgery, one week for systemic treatment and four weeks for radiotherapy.[12]The Strategy does not specify a consolidated overall budget, detailed financing plan or quantified funding gap, although it identifies research funding, Health Cohesion Fund compensation for cross-regional specialist referrals and resource pressures from treatment innovation as important considerations.[31][47][48]

Monitoring & Evaluation

The Strategy establishes a monitoring and evaluation system combining strategic indicators, cancer registries, screening information systems, clinical audits and data reported by the Ministry of Health and autonomous communities. Indicators are designed as process or outcome measures to assess effectiveness and provide clear, consistent and current information.[23][33][41]

• Use a Follow-up and Evaluation Committee, created in 2007 from the Technical and Institutional Committees, to establish the monitoring system. The first evaluation in 2008 informed the 2010 update, and a further evaluation in 2014 informed the current revision.[23][1]
• Collect evaluation information from autonomous communities and the Ministry of Health, including through the Health Information Institute, the cancer screening programmes network, the Spanish Network of Cancer Registries and the Carlos III Health Institute.[23]
• Apply indicators structured by strategic line, objective, formula, data source and responsible institution, combining National Health System data with questionnaire data agreed with the monitoring committee.[41]
• Monitor population health and prevention through indicators on diet, obesity, sedentary behaviour, alcohol and tobacco use, occupational exposure, radon burden, and hepatitis B and human papillomavirus vaccination coverage.[49][50][51][52][53]
• Track vaccination targets of over 95% hepatitis B coverage among children aged 12 months and over 80% complete human papillomavirus vaccination among 15-year-olds, disaggregated by autonomous community.[54]
• Assess organised screening through invitation coverage, participation, detection rates and follow-up. Indicative standards include over 85% coverage and over 70% participation for breast screening, over 85% coverage and at least 70% participation for cervical screening, and at least 65% participation for colorectal screening.[55][56][57][58][59]
• Require autonomous communities and autonomous cities to maintain screening information systems and annual evaluation reports for breast, colorectal and cervical programmes.[60][61]
• Monitor rapid diagnosis and treatment intervals through audits, including targets of seven days from primary-care referral to first hospital visit, 15 days to pathological diagnosis or exclusion, four weeks where molecular diagnosis is required, and treatment medians of two weeks for surgery, one week for systemic treatment and four weeks for radiotherapy.[12][46][62][63][64]
• Assess hospital cancer care through the availability and use of multidisciplinary tumour committees, systematic recording of therapeutic decisions, audits, survival by stage, recurrence and 30-day or same-admission surgical mortality.[65][33][61][29][66]
• Monitor specialist reference services through accreditation, on-site audits, annual follow-up of activity and clinical-outcome requirements, patient registries, and indicators for designated units and networked cancer-care models.[31][67][32][68]
• Strengthen surveillance through population-based registries measuring incidence, prevalence, mortality and five-year survival. Adult net survival uses the Pohar-Perme estimator, while observed survival uses Kaplan-Meier methods.[20][69][44][70]
• Improve registry completeness, stage, multimorbidity, recurrence and follow-up information, while expanding coverage from approximately 27% towards potential coverage of 53% through registry consolidation.[20][71]
• Monitor childhood cancer through the Spanish Registry of Childhood Tumours, including incidence, five-year survival, follow-up completeness and coverage; approximately 95% follow-up is identified as the level needed for reliable survival estimates.[45][72]
• Require outcome feedback from cancer hospitals to clinical teams and tumour committees, followed by improvement measures, creating a direct accountability mechanism for service quality.[33]
• Assess equity in the national and regional cancer strategies using the methodological guide for integrating equity into health strategies, programmes and activities.[73]

Costing & Financing

The Strategy does not provide a consolidated national budget, costed implementation plan, quantified funding gap or economic assumptions. It identifies financing needs and economic assessments for research, prevention, specialised care, technology and screening, but generally does not attach monetary values.[1][74][75][24][33]

• Prioritise cancer research financing through the Carlos III Health Institute, autonomous-community plans and calls, specialised centres, non-profit organisations and private funding. The Spanish Association Against Cancer is identified as a leading private funder, while financing for the Spanish Clinical Research Network platform is described as limited.[48]
• Monitor annual cancer funding within the Health Strategic Action, the proportion of cancer funding in total annual funding, the number of funded projects and average funding per project, although no amounts are supplied.[76][77]
• Recognise pressure on health-system resources from population ageing, growing cancer incidence and increasingly costly cancer treatment, including the potential impact on access to therapeutic innovation.[11][47]
• Use clinical-benefit assessment to judge whether treatment costs are proportionate to gains in survival, quality of life and toxicity outcomes; medicine prices are noted not to correlate consistently with clinical benefit.[47][78]
• Assess cost-effectiveness, diagnostic-evaluation costs, resource requirements and feasibility before any introduction of lung-cancer screening.[9][79][80][81]
• Recognise colorectal screening as highly cost-effective because it supports early detection and removal of precursor lesions, potentially reducing incidence and generating savings.[82]
• Use tobacco and alcohol taxation and pricing policies as prevention and resource-mobilisation measures. Tobacco-cessation programmes delivered through the health system are described as cost-effective, but no expenditure or revenue estimate is provided.[83][84][85]
• Recognise tobacco use as generating direct costs from morbidity and mortality and indirect costs from productivity losses and suffering, without quantification.[86][83]
• Finance cross-regional care in designated reference units through the Health Cohesion Fund, although no allocation or reimbursement amount is specified.[31]
• Identify positive benefit-to-cost evidence for human papillomavirus vaccination and call for estimation of healthcare costs attributable to occupational cancer, but provide neither a value nor a financing commitment.[87][88][52][51]
• Note that Spain's precision-oncology financing model remains undefined; a French National Cancer Institute programme is cited as an external example of financing for biomarker access and related clinical research.[40]